• Design and synthesis of small and selective heterocyclic molecules as potential therapeutics of memory impairment targeting α5-containing GABAA receptors, GlyT1, MAO-B and NOP• Supervised and worked on several distinct scaffolds in MAO-B project resulting in 2 lead compounds, DNS-1216252 and DNS-1215881, as the back-ups of our clinical candidate HT-3951• Point person in the MAO-B project responsible for compound stability, CYP inhibition and PK studies• Experience in managing CRO for custom synthesis• Experience in supervision, mentorship, and development of other scientists• Experience working with computational chemists as part of project team in design of drug targets • Attended the 2011 short course: “Drug-like Properties: Optimizing Pharmacokinetics and Safety in Drug Discovery” organized by ACS in San Diego, CA• Attended the 2010 short course: “Drug Development and Non-clinical Safety Evaluation of Drugs and Biologics” provided by Dr. Shayne C. Gad• Attended the 2010 short course: “Structure Based Drug Design” organized by ACS in San Diego, CA• 2011 On the Spot Award: confirmation of the regio-chemistry of HT-3951, a clinical candidate of MAO-B inhibitor, and the identification of a chemical process facilitating the synthesis of radio-labeled HT-3951 as potential PET ligand

• Developed small molecule efflux pump inhibitors (EPIs) to reverse efflux-mediated resistance to antibiotics in gram-negative bacteria• Assisted in setting up the new chemistry laboratory, including hiring of new chemists, purchasing chemicals, glasswares and equipment in a cost effective manner• Assisted in setting up and maintaining the mass spectrometer and developing general methods for reaction monitoring and final compound purity assessment• Extensive experience in peptide and heterocyclic chemistry

• Design and synthesis of TG101348 (Fedratinib), FDA approved JAK2 selective inhibitor to treat myeloproliferative diseases (MPD)• Co-identified TG100801, a prodrug targeting VEGFR/Src in the ocular program advanced to Phase II clinical trial• Successfully developed multiple new generation of JAK2 inhibitors with good PK and selectivity profiles• Demonstrated medicinal chemistry expertise across multiple programs targeting JAK, SRC, ABL, PI3K and VEGFr2• Track record of applying computational chemistry in guiding chemistry optimization• Actively supported development activities for our nominated compounds including primary reference standard preparation, residual solvent removal, salt selection and polymorph studies• Participated in scaling up of compounds in various projects for PK profiling and efficacy studies• Contributed to build IP portfolio in each program and assisted in patent writing and conversion filings • Co-author of >15 patents/patent applications, 10 scientific publications and >15 conference presentations• Attended the 2006 short course on pharmacokinetics organized by MedChem USA in San Diego, CA

• Developed the new and patentable scaffolds as mineralocorticoid receptor antagonists in the cardiovascular program• Experience in solution phase parallel synthesis of focused libraries• Experience in employing automation and robotics for small organic molecule purification• Attended the 2003 heterocyclic chemistry course provided by Profs. Albert Padwa and William H. Pearson

• Synthesis and SAR study of small, heterocyclic molecules as malonylCoA decarboxylase (MCD) inhibitors in the cardiovascular program• Experience in solid and solution phase synthesis of small heterocyclic molecules• Successfully synthesized a new class of compounds as a backup series for the pre-clinical candidate• Participated in the multi-step synthesis and scale-up of key molecules for toxicology studies• Attended the 2002 residential school on medicinal chemistry at Drew University, NJ